SSA
AZN icon

Schonfeld Strategic Advisors’s AstraZeneca AZN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-225,000
Closed -$485K – 1775
2023
Q2 		$485K Buy
225,000
+75,000
+50% +$11M ﹤0.01% 1234
2023
Q1 		$1.05M Buy
+150,000
New +$20.2M 0.01% 938

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Schonfeld Strategic Advisors's AZN Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its AstraZeneca (AZN) stake by 2.6% in Q1 2026, buying an estimated $202K and bringing the position to 42,071 shares worth $8.3M. The position accounts for 0.06% of the portfolio, ranked #345.

Schonfeld Strategic Advisors first reported a position in AZN in Q1 2016 and has held it in 26 quarters since. The position peaked at $66.6M in Q3 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Schonfeld Strategic Advisors held 42,071 shares of AstraZeneca worth $8.3M as of Q1 2026.
  • Schonfeld Strategic Advisors bought 1,047 AstraZeneca shares in Q1 2026, an estimated $202K.
  • AstraZeneca made up 0.06% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #345 holding.
  • Schonfeld Strategic Advisors first reported a position in AstraZeneca in Q1 2016 and has held it in 26 quarters since.
  • Schonfeld Strategic Advisors's AstraZeneca position peaked at $66.6M in Q3 2025.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.